Crohn's Disease: Therapeutic Updates, Barriers to Care, and Emerging Therapies (CME)

In this online self-learning program: Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are Crohn’s disease and ulcerative colitis, the former of which affects any area of the alimentary canal. There are up to about fifteen new Crohn’s disease cases per 100,000 people per year, with…

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are Crohn’s disease and ulcerative colitis, the former of which affects any area of the alimentary canal. There are up to about fifteen new Crohn’s disease cases per 100,000 people per year, with the vast majority occurring in the North American continent, the United Kingdom (UK), and northern Europe. Given the data from multiple studies that physicians are either not aware of updated practice guidelines or are not utilizing them and that this lack of knowledge is affecting patient satisfaction, CME programs are warranted to keep HCPs abreast of best practices. There have been many advances on both diagnostic and treatment sides, as well as a wide array of advances in care in pharmacotherapeutic options, including approved therapies as well as potential ones on the horizon, meriting CME.

Program Objectives:

1. Describe the strengths and weaknesses of present and emerging diagnostic techniques, where applicable in Crohn’s disease
2. Describe strengths of different professional organizations’ guidance in Crohn’s disease diagnosis and treatment guidelines
3. Describe emerging therapies in the treatment of Crohn’s disease.
4. Describe barriers to care in the treatment of Crohn’s disease and suggest ways to ameliorate them.
5. Identify the present treatment options currently available for management of Crohn’s disease and apply them to patient cases using evidence-based medicine.

Credit Designation:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians. ScientiaCME designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.